Cheap and widespread drug dexamethasone has successfully passed clinical studies among patients hospitalized with coronavirus infection. As shown by the results of the RECOVERY studies, application of dexamethasone for about a third of the reduced mortality among patients on mechanical ventilation because of COVID-19, writes Nature.
A randomized clinical trial RECOVERY was initiated in the UK in March 2020. It has become one of the largest research therapy coronavirus infection – it took part 2.1 thousand patients receiving dexamethasone, as well as 4.3 thousand patients receiving standard therapy COVID-19.
The greatest efficiency of dexamethasone was observed among patients with severe infection: mortality among patients on mechanical ventilation decreased by 35%, and among patients receiving supplemental oxygen at 20%. While the steroid drug did not help patients with mild form of coronavirus infection.
After obtaining convincing results KEY the UK government announced the immediate approval of the use of dexamethasone in patients hospitalized with COVID-19.